Join

Compare · NVO vs TXMD

NVO vs TXMD

Side-by-side comparison of Novo Nordisk A/S (NVO) and TherapeuticsMD Inc. (TXMD): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVO and TXMD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $187.53B, about 8224.5x TXMD ($22.8M).
  • NVO has been more active in the news (11 items in the past 4 weeks vs 3 for TXMD).
  • NVO has more recent analyst coverage (25 ratings vs 2 for TXMD).
MetricNVOTXMD
Company
Novo Nordisk A/S
TherapeuticsMD Inc.
Price
-
-
Market cap
$187.53B
$22.8M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
News (4w)
11
3
Recent ratings
25
2
NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

TXMD

TherapeuticsMD Inc.

TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-007HR and TX-008HR, which are transdermal patch product candidates. The company's clinical development product is TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.